Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 MillionGlobeNewsWire • 06/30/22
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty PharmaPRNewsWire • 06/30/22
Royalty Pharma (RPRX) Surges 5.2%: Is This an Indication of Further Gains?Zacks Investment Research • 06/27/22
Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare ConferenceGlobeNewsWire • 06/08/22
Royalty Pharma plc (RPRX) Management on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022GlobeNewsWire • 04/13/22
Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and TreatmentPRNewsWire • 03/29/22
Royalty Pharma's (RPRX) CEO Pablo Legorreta on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/15/22
Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022GlobeNewsWire • 01/20/22
Royalty Pharma (RPRX) Surges 5.4%: Is This an Indication of Further Gains?Zacks Investment Research • 01/11/22
Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/10/22
Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 MillionGlobeNewsWire • 01/07/22